inspirator schreef op 21 april 2016 08:23:
The 20-week results from filgotinib in Crohn’s disease (FITZROY) are expected in April. Galapagos and Gilead are preparing to initiate Phase 3 programs in rheumatoid arthritis and Crohn’s disease with filgotinib in 2016.
We are ready to advance the most effective combination therapy in CF to patient studies, to progress the rest of our promising pipeline, and to work with our collaboration partner Gilead to get the Phase 3 programs with filgotinib in rheumatoid arthritis and Crohn’s disease under way.